# Cumberland Pharmaceuticals Inc: financial statements, quarterly

CPIX · Nasdaq · CIK 1087294 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cpix.md) · [Financials](/companies/cpix/financials.md) · [Filings](/companies/cpix/filings.md) · [Insiders](/companies/cpix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cpix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.1](/filings/0001628280-25-011366.md) | [9.4](/filings/0001628280-25-011366.md) | [8.5](/filings/0001087294-26-000020.md) | [9.8](/filings/0001087294-26-000020.md) | [9.1](/filings/0001087294-26-000020.md) | [10.4](/filings/0001087294-26-000020.md) | [11.7](/filings/0001087294-26-000049.md) | [10.8](/filings/0001087294-26-000062.md) | [8.3](/filings/0001087294-26-000020.md) | [13.7](/filings/0001087294-26-000020.md) | [9.1](/filings/0001087294-26-000049.md) | [8.8](/filings/0001087294-26-000062.md) |
| Cost of revenue | $m | [1.8](/filings/0001628280-24-046730.md) | [1.5 d](/filings/0001628280-25-011366.md) | [1.6](/filings/0001628280-25-024342.md) | [1.7](/filings/0001628280-25-039326.md) | [1.3](/filings/0001087294-25-000020.md) | [2.0 d](/filings/0001087294-26-000020.md) | [1.4](/filings/0001087294-26-000049.md) | [2.0](/filings/0001628280-25-039326.md) | [1.0](/filings/0001087294-25-000020.md) | [2.2 d](/filings/0001087294-26-000020.md) | [1.9](/filings/0001087294-26-000049.md) | not reported |
| Research and development | $m | [1.9](/filings/0001628280-24-046730.md) | [1.3 d](/filings/0001628280-25-011366.md) | [1.2](/filings/0001628280-25-024342.md) | [1.1](/filings/0001628280-25-039326.md) | [1.3](/filings/0001087294-25-000020.md) | [1.3 d](/filings/0001087294-26-000020.md) | [1.3](/filings/0001087294-26-000049.md) | [0.8](/filings/0001087294-26-000062.md) | [1.3](/filings/0001087294-25-000020.md) | [1.5 d](/filings/0001087294-26-000020.md) | [1.5](/filings/0001087294-26-000049.md) | [0.8](/filings/0001087294-26-000062.md) |
| Operating income | $m | [(1.9)](/filings/0001628280-25-011366.md) | [(6.2)](/filings/0001628280-25-011366.md) | [(1.9)](/filings/0001087294-26-000020.md) | [(1.0)](/filings/0001087294-26-000020.md) | [(1.7)](/filings/0001087294-26-000020.md) | [(1.8)](/filings/0001087294-26-000020.md) | [1.3](/filings/0001087294-26-000049.md) | [(3.1)](/filings/0001087294-26-000062.md) | [(2.0)](/filings/0001087294-26-000020.md) | [(1.4)](/filings/0001087294-26-000020.md) | [(3.1)](/filings/0001087294-26-000049.md) | [(3.2)](/filings/0001087294-26-000062.md) |
| Interest expense | $m | [0.1](/filings/0001628280-24-046730.md) | [0.2 d](/filings/0001628280-25-011366.md) | [0.1](/filings/0001628280-25-024342.md) | [0.1](/filings/0001628280-25-039326.md) | [0.1](/filings/0001087294-25-000020.md) | [0.2 d](/filings/0001087294-26-000020.md) | [0.2](/filings/0001087294-26-000049.md) | [0.0](/filings/0001087294-26-000062.md) | [0.1](/filings/0001087294-25-000020.md) | [0.1 d](/filings/0001087294-26-000020.md) | [0.1](/filings/0001087294-26-000049.md) | [0.0](/filings/0001087294-26-000062.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-046730.md) | [0.0 d](/filings/0001628280-25-011366.md) | [0.0](/filings/0001628280-25-024342.md) | [0.0](/filings/0001628280-25-039326.md) | [0.0](/filings/0001087294-25-000020.md) | [(0.1) d](/filings/0001087294-26-000020.md) | [0.0](/filings/0001087294-26-000049.md) | [0.0](/filings/0001087294-26-000062.md) | [0.0](/filings/0001087294-25-000020.md) | [0.0 d](/filings/0001087294-26-000020.md) | [0.0](/filings/0001087294-26-000049.md) | [0.0](/filings/0001087294-26-000062.md) |
| Net income | $m | [(1.0)](/filings/0001628280-25-011366.md) | [(6.3)](/filings/0001628280-25-011366.md) | [(1.9)](/filings/0001087294-26-000020.md) | [(1.1)](/filings/0001087294-26-000020.md) | [(1.5)](/filings/0001087294-26-000020.md) | [(1.9)](/filings/0001087294-26-000020.md) | [1.3](/filings/0001087294-26-000049.md) | [(0.7)](/filings/0001087294-26-000062.md) | [(1.9)](/filings/0001087294-26-000020.md) | [(1.4)](/filings/0001087294-26-000020.md) | [(3.3)](/filings/0001087294-26-000049.md) | [(4.3)](/filings/0001087294-26-000062.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001628280-24-046730.md) | [(0.44)](/filings/0001628280-24-010725.md) | [(0.14)](/filings/0001628280-25-024342.md) | [(0.08)](/filings/0001628280-25-039326.md) | [(0.11)](/filings/0001087294-25-000020.md) | [(0.14)](/filings/0001628280-25-011366.md) | [0.08](/filings/0001087294-26-000049.md) | [(0.05)](/filings/0001087294-26-000062.md) | [(0.13)](/filings/0001087294-26-000020.md) | [(0.09)](/filings/0001087294-26-000020.md) | [(0.22)](/filings/0001087294-26-000049.md) | [(0.29)](/filings/0001087294-26-000062.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001628280-24-046730.md) | [(0.44)](/filings/0001628280-24-010725.md) | [(0.14)](/filings/0001628280-25-024342.md) | [(0.08)](/filings/0001628280-25-039326.md) | [(0.11)](/filings/0001087294-25-000020.md) | [(0.14)](/filings/0001628280-25-011366.md) | [0.08](/filings/0001087294-26-000049.md) | [(0.05)](/filings/0001087294-26-000062.md) | [(0.13)](/filings/0001087294-26-000020.md) | [(0.09)](/filings/0001087294-26-000020.md) | [(0.22)](/filings/0001087294-26-000049.md) | [(0.29)](/filings/0001087294-26-000062.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.5](/filings/0001628280-23-038418.md) | [18.3](/filings/0001628280-25-011366.md) | [18.5](/filings/0001628280-24-022658.md) | [17.3](/filings/0001628280-24-036529.md) | [17.5](/filings/0001628280-24-046730.md) | [18.0](/filings/0001087294-26-000020.md) | [15.1](/filings/0001628280-25-024342.md) | [16.1](/filings/0001628280-25-039326.md) | [15.2](/filings/0001087294-25-000020.md) | [11.4](/filings/0001087294-26-000062.md) | [11.0](/filings/0001087294-26-000049.md) | [3.9](/filings/0001087294-26-000062.md) |
| Current assets | $m | [41.8](/filings/0001628280-23-038418.md) | [35.7](/filings/0001628280-25-011366.md) | [36.2](/filings/0001628280-24-022658.md) | [35.6](/filings/0001628280-24-036529.md) | [35.2](/filings/0001628280-24-046730.md) | [36.5](/filings/0001087294-26-000020.md) | [31.9](/filings/0001628280-25-024342.md) | [31.2](/filings/0001628280-25-039326.md) | [29.9](/filings/0001087294-25-000020.md) | [37.1](/filings/0001087294-26-000062.md) | [32.8](/filings/0001087294-26-000049.md) | [33.6](/filings/0001087294-26-000062.md) |
| Total assets | $m | [87.8](/filings/0001628280-23-038418.md) | [81.8](/filings/0001628280-25-011366.md) | [81.5](/filings/0001628280-24-022658.md) | [78.5](/filings/0001628280-24-036529.md) | [76.7](/filings/0001628280-24-046730.md) | [75.6](/filings/0001087294-26-000020.md) | [69.9](/filings/0001628280-25-024342.md) | [67.9](/filings/0001628280-25-039326.md) | [65.9](/filings/0001087294-25-000020.md) | [76.8](/filings/0001087294-26-000062.md) | [71.0](/filings/0001087294-26-000049.md) | [62.9](/filings/0001087294-26-000062.md) |
| Current liabilities | $m | [27.3](/filings/0001628280-23-038418.md) | [28.0](/filings/0001628280-25-011366.md) | [26.4](/filings/0001628280-24-022658.md) | [24.8](/filings/0001628280-24-036529.md) | [31.1](/filings/0001628280-24-046730.md) | [31.6](/filings/0001087294-26-000020.md) | [25.5](/filings/0001628280-25-024342.md) | [24.0](/filings/0001628280-25-039326.md) | [24.3](/filings/0001087294-25-000020.md) | [36.7](/filings/0001087294-26-000062.md) | [34.5](/filings/0001087294-26-000049.md) | [35.2](/filings/0001087294-26-000062.md) |
| Total liabilities | $m | [52.1](/filings/0001628280-23-038418.md) | [52.5](/filings/0001628280-25-011366.md) | [54.3](/filings/0001628280-24-022658.md) | [52.5](/filings/0001628280-24-036529.md) | [52.3](/filings/0001628280-24-046730.md) | [53.0](/filings/0001087294-26-000020.md) | [41.6](/filings/0001628280-25-024342.md) | [40.2](/filings/0001628280-25-039326.md) | [40.1](/filings/0001087294-25-000020.md) | [52.3](/filings/0001087294-26-000062.md) | [49.7](/filings/0001087294-26-000049.md) | [45.8](/filings/0001087294-26-000062.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001628280-25-011366.md) | not reported | not reported | not reported | [5.1](/filings/0001087294-26-000020.md) | not reported | not reported | not reported | [0.0](/filings/0001087294-26-000020.md) | not reported | not reported |
| Shareholders' equity | $m | [36.0](/filings/0001628280-23-038418.md) | [29.6](/filings/0001628280-25-011366.md) | [27.5](/filings/0001628280-24-022658.md) | [26.3](/filings/0001628280-24-036529.md) | [24.8](/filings/0001628280-24-046730.md) | [22.9](/filings/0001087294-26-000020.md) | [28.7](/filings/0001628280-25-024342.md) | [28.0](/filings/0001628280-25-039326.md) | [26.1](/filings/0001087294-25-000020.md) | [24.9](/filings/0001087294-26-000062.md) | [21.6](/filings/0001087294-26-000049.md) | [17.4](/filings/0001087294-26-000062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,237 d](/filings/0001628280-24-046730.md) | [1,040 d](/filings/0001628280-25-011366.md) | [(2,137)](/filings/0001628280-25-024342.md) | [(856) d](/filings/0001628280-25-039326.md) | [476 d](/filings/0001087294-25-000020.md) | [1,905 d](/filings/0001087294-26-000020.md) | [3,899](/filings/0001087294-26-000049.md) | [844 d](/filings/0001087294-26-000062.md) | [187 d](/filings/0001087294-25-000020.md) | [3.0 d](/filings/0001087294-26-000020.md) | [387](/filings/0001087294-26-000049.md) | [169 d](/filings/0001087294-26-000062.md) |
| Capital expenditure | $k | [53.1 d](/filings/0001628280-24-046730.md) | [48.7 d](/filings/0001628280-25-011366.md) | [41.6](/filings/0001628280-25-024342.md) | [7.2 d](/filings/0001628280-25-039326.md) | [15.4 d](/filings/0001087294-25-000020.md) | [2.3 d](/filings/0001087294-26-000020.md) | [47.6](/filings/0001087294-26-000049.md) | [26.5 d](/filings/0001087294-26-000062.md) | [23.8 d](/filings/0001087294-25-000020.md) | [(0.0) d](/filings/0001087294-26-000020.md) | [0.0](/filings/0001087294-26-000049.md) | [38.3 d](/filings/0001087294-26-000062.md) |
| Share repurchases | $k | [202 d](/filings/0001628280-24-046730.md) | [189 d](/filings/0001628280-25-011366.md) | [248](/filings/0001628280-25-024342.md) | [134 d](/filings/0001628280-25-039326.md) | [98.8 d](/filings/0001087294-25-000020.md) | [98.4 d](/filings/0001087294-26-000020.md) | [246](/filings/0001087294-26-000049.md) | [7.2 d](/filings/0001087294-26-000062.md) | [10.4 d](/filings/0001087294-25-000020.md) | [0.0 d](/filings/0001087294-26-000020.md) | [61.0](/filings/0001087294-26-000049.md) | [0.0 d](/filings/0001087294-26-000062.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.5](/filings/0001628280-23-038418.md) | [14.6](/filings/0001628280-24-022658.md) | [14.6](/filings/0001628280-24-036529.md) | [14.3](/filings/0001628280-24-046730.md) | [14.1](/filings/0001628280-25-024342.md) | [14.1](/filings/0001628280-25-039326.md) | [14.1](/filings/0001087294-25-000020.md) | [15.3](/filings/0001087294-26-000049.md) | [15.0](/filings/0001087294-26-000062.md) | [15.0](/filings/0001087294-25-000020.md) | [15.0](/filings/0001087294-26-000049.md) | [15.0](/filings/0001087294-26-000062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,983,107 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001087294-26-000062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.